BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 32588670)

  • 1. Discontinuation of immunoglobulin replacement therapy in patients with secondary antibody deficiency.
    Patel V; Cowan J
    Expert Rev Clin Immunol; 2020 Jul; 16(7):711-716. PubMed ID: 32588670
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current clinical practice and challenges in the management of secondary immunodeficiency in hematological malignancies.
    Na IK; Buckland M; Agostini C; Edgar JDM; Friman V; Michallet M; Sánchez-Ramón S; Scheibenbogen C; Quinti I
    Eur J Haematol; 2019 Jun; 102(6):447-456. PubMed ID: 30801785
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A systematic literature review of the effects of immunoglobulin replacement therapy on the burden of secondary immunodeficiency diseases associated with hematological malignancies and stem cell transplants.
    Monleón Bonet C; Waser N; Cheng K; Tzivelekis S; Edgar JDM; Sánchez-Ramón S
    Expert Rev Clin Immunol; 2020 Sep; 16(9):911-921. PubMed ID: 32783541
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunoglobulin replacement for secondary immunodeficiency after B-cell targeted therapies in autoimmune rheumatic disease: Systematic literature review.
    Wijetilleka S; Mukhtyar C; Jayne D; Ala A; Bright P; Chinoy H; Harper L; Kazmi M; Kiani-Alikhan S; Li C; Misbah S; Oni L; Price-Kuehne F; Salama A; Workman S; Wrench D; Karim MY
    Autoimmun Rev; 2019 May; 18(5):535-541. PubMed ID: 30844552
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prophylactic immunoglobulin therapy in secondary immune deficiency - an expert opinion.
    Agostini C; Blau IW; Kimby E; Plesner T
    Expert Rev Clin Immunol; 2016 Sep; 12(9):921-6. PubMed ID: 27415820
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of immunoglobulin replacement therapy in patients with secondary antibody deficiency in daily practice: a European expert Q&A-based review.
    Cinetto F; Francisco IE; Fenchel K; Scarpa R; Montefusco V; Pluta A; Wolf HM
    Expert Rev Hematol; 2023 Apr; 16(4):237-243. PubMed ID: 37009667
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A French observational study describing the use of human polyvalent immunoglobulins in hematological malignancy-associated secondary immunodeficiency.
    Benbrahim O; Viallard JF; Choquet S; Royer B; Bauduer F; Decaux O; Crave JC; Fardini Y; Clerson P; Lévy V
    Eur J Haematol; 2018 Jul; 101(1):48-56. PubMed ID: 29644723
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk Factors of Pneumonia in Primary Antibody Deficiency Patients Receiving Immunoglobulin Therapy: Data from the US Immunodeficiency Network (USIDNET).
    Syed MN; Kutac C; Miller JM; Marsh R; Sullivan KE; Cunningham-Rundles C; Fuleihan RL; Kheradmand F; Hajjar J
    J Clin Immunol; 2022 Oct; 42(7):1545-1552. PubMed ID: 35779201
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibody replacement therapy in primary antibody deficiencies and iatrogenic hypogammaglobulinemia.
    Hoffman TW; van Kessel DA; van Velzen-Blad H; Grutters JC; Rijkers GT
    Expert Rev Clin Immunol; 2015; 11(8):921-33. PubMed ID: 26181342
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reduced risk of infections with the intravenous immunoglobulin, IgPro10, in patients at risk of secondary immunodeficiency-related infections.
    Lahue BJ; Mallick R; Zhang X; Heidt J; Song Y; Koenig AS; Espinoza G
    Immunotherapy; 2022 Oct; 14(15):1245-1261. PubMed ID: 35971794
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Utilization of intravenous or subcutaneous immunoglobulins in secondary immune deficiency (ULTIMATE): A retrospective multicenter study.
    Legendre P; Chahwan D; Marjanovic Z; Vignon M; Hermine O; Lortholary O; Morelle G; Darrodes M; Kahn JE; Ouzegdouh M; Chaibi P; Montestruc F; Caumont-Prim A; Le Jouan M; Hassani Y; Godeau B; Durand-Zaleski I; Mouthon L
    Clin Immunol; 2020 Jun; 215():108419. PubMed ID: 32289463
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Humoral Immunodeficiency and Immune Globulin Replacement Therapy (IGRT) Usage in DiGeorge Syndrome.
    Soshnick SH; Joseph T; Bennett NJ
    J Clin Immunol; 2021 Aug; 41(6):1208-1212. PubMed ID: 33740168
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Infections in secondary immunodeficiency patients treated with Privigen
    Mallick R; Divino V; Smith BD; Jolles S; DeKoven M; Vinh DC
    Leuk Lymphoma; 2021 Dec; 62(14):3463-3473. PubMed ID: 34569910
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical use of immune serum globulin as replacement therapy in patients with primary immunodeficiency syndromes.
    Schwartz SA
    Clin Rev Allergy; 1992; 10(1-2):1-12. PubMed ID: 1606517
    [TBL] [Abstract][Full Text] [Related]  

  • 15. When to initiate immunoglobulin replacement therapy (IGRT) in antibody deficiency: a practical approach.
    Jolles S; Chapel H; Litzman J
    Clin Exp Immunol; 2017 Jun; 188(3):333-341. PubMed ID: 28000208
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recommendations for Management of Secondary Antibody Deficiency in Multiple Myeloma.
    Giralt S; Jolles S; Kerre T; Lazarus HM; Mustafa SS; Papanicolaou GA; Ria R; Vinh DC; Wingard JR
    Clin Lymphoma Myeloma Leuk; 2023 Oct; 23(10):719-732. PubMed ID: 37353432
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treating secondary antibody deficiency in patients with haematological malignancy: European expert consensus.
    Jolles S; Michallet M; Agostini C; Albert MH; Edgar D; Ria R; Trentin L; Lévy V
    Eur J Haematol; 2021 Apr; 106(4):439-449. PubMed ID: 33453130
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reversible Hypogammaglobulinemia in 2 Pediatric Patients With Primary Immunodeficiency.
    Pasic S
    J Investig Allergol Clin Immunol; 2017; 27(5):320-321. PubMed ID: 29057740
    [No Abstract]   [Full Text] [Related]  

  • 19. Treatment of antibody immunodeficiency.
    Litzman J
    Vnitr Lek; 2019; 65(2):126-130. PubMed ID: 30909702
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunoglobulin replacement in hematological malignancies: a focus on evidence, alternatives, dosing strategy, and cessation rule.
    Sim B; Ng JY; Teh BW; Talaulikar D
    Leuk Lymphoma; 2023 Jan; 64(1):18-29. PubMed ID: 36218218
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.